|Assessment Status||Rapid Review Complete|
|Indication||As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.|
|Rapid review commissioned||22/12/2021|
|Rapid review completed||13/01/2022|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that lorlatinib not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.